FDA Inspection 1052038 — Piedmont Reproductive Endocrinology Group, PA
The FDA completed an inspection of Piedmont Reproductive Endocrinology Group, PA on Apr 11, 2018 in Asheville, NC. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Apr 11, 2018
- Fiscal Year
- 2018
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Asheville, NC (United States)